472 related articles for article (PubMed ID: 34253636)
1. PD-1
Li JP; Wu CY; Chen MY; Liu SX; Yan SM; Kang YF; Sun C; Grandis JR; Zeng MS; Zhong Q
J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34253636
[TBL] [Abstract][Full Text] [Related]
2. CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer.
Yang M; Lu J; Zhang G; Wang Y; He M; Xu Q; Xu C; Liu H
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33452206
[TBL] [Abstract][Full Text] [Related]
3. Tertiary Lymphoid Structure-Associated B Cells Enhance CXCL13
Hu C; You W; Kong D; Huang Y; Lu J; Zhao M; Jin Y; Peng R; Hua D; Kuang DM; Chen Y
Gastroenterology; 2024 Jun; 166(6):1069-1084. PubMed ID: 38445519
[TBL] [Abstract][Full Text] [Related]
4. Adaptive antitumor immune response stimulated by bio-nanoparticle based vaccine and checkpoint blockade.
Bai X; Zhou Y; Yokota Y; Matsumoto Y; Zhai B; Maarouf N; Hayashi H; Carlson R; Zhang S; Sousa A; Sun B; Ghanbari H; Dong X; Wands JR
J Exp Clin Cancer Res; 2022 Apr; 41(1):132. PubMed ID: 35392977
[TBL] [Abstract][Full Text] [Related]
5. Immunological potential of tertiary lymphoid structures surrounding the primary tumor in gastric cancer.
Yamakoshi Y; Tanaka H; Sakimura C; Deguchi S; Mori T; Tamura T; Toyokawa T; Muguruma K; Hirakawa K; Ohira M
Int J Oncol; 2020 Jul; 57(1):171-182. PubMed ID: 32319601
[TBL] [Abstract][Full Text] [Related]
6. Tertiary lymphoid structures show infiltration of effective tumor-resident T cells in gastric cancer.
Mori T; Tanaka H; Suzuki S; Deguchi S; Yamakoshi Y; Yoshii M; Miki Y; Tamura T; Toyokawa T; Lee S; Muguruma K; Wanibuchi H; Ohira M
Cancer Sci; 2021 May; 112(5):1746-1757. PubMed ID: 33735485
[TBL] [Abstract][Full Text] [Related]
7. TGF-β-mediated silencing of genomic organizer SATB1 promotes Tfh cell differentiation and formation of intra-tumoral tertiary lymphoid structures.
Chaurio RA; Anadon CM; Lee Costich T; Payne KK; Biswas S; Harro CM; Moran C; Ortiz AC; Cortina C; Rigolizzo KE; Sprenger KB; Mine JA; Innamarato P; Mandal G; Powers JJ; Martin A; Wang Z; Mehta S; Perez BA; Li R; Robinson J; Kroeger JL; Curiel TJ; Yu X; Rodriguez PC; Conejo-Garcia JR
Immunity; 2022 Jan; 55(1):115-128.e9. PubMed ID: 35021053
[TBL] [Abstract][Full Text] [Related]
8. Cancer-associated fibroblasts drive CXCL13 production in activated T cells via TGF-beta.
O'Connor RA; Martinez BR; Koppensteiner L; Mathieson L; Akram AR
Front Immunol; 2023; 14():1221532. PubMed ID: 37520560
[TBL] [Abstract][Full Text] [Related]
9. CXCL13-producing CD4+ T cells accumulate in the early phase of tertiary lymphoid structures in ovarian cancer.
Ukita M; Hamanishi J; Yoshitomi H; Yamanoi K; Takamatsu S; Ueda A; Suzuki H; Hosoe Y; Furutake Y; Taki M; Abiko K; Yamaguchi K; Nakai H; Baba T; Matsumura N; Yoshizawa A; Ueno H; Mandai M
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35552285
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral CXCL13
Dai S; Zeng H; Liu Z; Jin K; Jiang W; Wang Z; Lin Z; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Liu L; Zhu Y; Xu L; Qu Y; Guo J; Xu J
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589528
[TBL] [Abstract][Full Text] [Related]
11. Single-cell profiling reveals the importance of CXCL13/CXCR5 axis biology in lymphocyte-rich classic Hodgkin lymphoma.
Aoki T; Chong LC; Takata K; Milne K; Marshall A; Chavez EA; Miyata-Takata T; Ben-Neriah S; Unrau D; Telenius A; Boyle M; Weng AP; Savage KJ; Scott DW; Farinha P; Shah SP; Nelson BH; Steidl C
Proc Natl Acad Sci U S A; 2021 Oct; 118(41):. PubMed ID: 34615710
[TBL] [Abstract][Full Text] [Related]
12. Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas.
Kinker GS; Vitiello GAF; Diniz AB; Cabral-Piccin MP; Pereira PHB; Carvalho MLR; Ferreira WAS; Chaves AS; Rondinelli A; Gusmão AF; Defelicibus A; Dos Santos GO; Nunes WA; Claro LCL; Bernardo TM; Nishio RT; Pacheco AM; Laus AC; Arantes LMRB; Fleck JL; de Jesus VHF; de Moricz A; Weinlich R; Coimbra FJF; de Lima VCC; Medina TDS
Gut; 2023 Oct; 72(10):1927-1941. PubMed ID: 37230755
[TBL] [Abstract][Full Text] [Related]
13. Tertiary lymphoid structures improve immunotherapy and survival in melanoma.
Cabrita R; Lauss M; Sanna A; Donia M; Skaarup Larsen M; Mitra S; Johansson I; Phung B; Harbst K; Vallon-Christersson J; van Schoiack A; Lövgren K; Warren S; Jirström K; Olsson H; Pietras K; Ingvar C; Isaksson K; Schadendorf D; Schmidt H; Bastholt L; Carneiro A; Wargo JA; Svane IM; Jönsson G
Nature; 2020 Jan; 577(7791):561-565. PubMed ID: 31942071
[TBL] [Abstract][Full Text] [Related]
14. Potential Role of CXCL13/CXCR5 Signaling in Immune Checkpoint Inhibitor Treatment in Cancer.
Hsieh CH; Jian CZ; Lin LI; Low GS; Ou PY; Hsu C; Ou DL
Cancers (Basel); 2022 Jan; 14(2):. PubMed ID: 35053457
[TBL] [Abstract][Full Text] [Related]
15. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic Cancer Chemotherapy Is Potentiated by Induction of Tertiary Lymphoid Structures in Mice.
Delvecchio FR; Fincham REA; Spear S; Clear A; Roy-Luzarraga M; Balkwill FR; Gribben JG; Bombardieri M; Hodivala-Dilke K; Capasso M; Kocher HM
Cell Mol Gastroenterol Hepatol; 2021; 12(5):1543-1565. PubMed ID: 34252585
[TBL] [Abstract][Full Text] [Related]
17. A Transcriptionally Distinct CXCL13
Workel HH; Lubbers JM; Arnold R; Prins TM; van der Vlies P; de Lange K; Bosse T; van Gool IC; Eggink FA; Wouters MCA; Komdeur FL; van der Slikke EC; Creutzberg CL; Kol A; Plat A; Glaire M; Church DN; Nijman HW; de Bruyn M
Cancer Immunol Res; 2019 May; 7(5):784-796. PubMed ID: 30872264
[TBL] [Abstract][Full Text] [Related]
18. Single-cell sequencing reveals the heterogeneity of B cells and tertiary lymphoid structures in muscle-invasive bladder cancer.
Yuan H; Mao X; Yan Y; Huang R; Zhang Q; Zeng Y; Bao M; Dai Y; Fang B; Mi J; Xie Y; Wang X; Zhang H; Mo Z; Yang R
J Transl Med; 2024 Jan; 22(1):48. PubMed ID: 38216927
[TBL] [Abstract][Full Text] [Related]
19. Tertiary lymphoid structures in the era of cancer immunotherapy.
Sautès-Fridman C; Petitprez F; Calderaro J; Fridman WH
Nat Rev Cancer; 2019 Jun; 19(6):307-325. PubMed ID: 31092904
[TBL] [Abstract][Full Text] [Related]
20. CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma.
Lin X; Zhao X; Chen Y; Yang R; Dai Z; Li W; Lin C; Cao W
Int J Immunopathol Pharmacol; 2024; 38():3946320241227312. PubMed ID: 38252495
[No Abstract] [Full Text] [Related]
[Next] [New Search]
